{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:52:53Z","timestamp":1794073973726,"version":"4.8.0"},"reference-count":238,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41575-025-01120-5","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:58:02Z","timestamp":1758887882000},"page":"866-884","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8540-4930","authenticated-orcid":false,"given":"Luis Antonio","family":"Diaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1854-1924","authenticated-orcid":false,"given":"Maja","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5293-007X","authenticated-orcid":false,"given":"Alexandre","family":"Louvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2108-1287","authenticated-orcid":false,"given":"Brian P.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5626-0942","authenticated-orcid":false,"given":"Veeral","family":"Ajmera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1720-4355","authenticated-orcid":false,"given":"Federica","family":"Tavaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2604-1340","authenticated-orcid":false,"given":"Cynthia L.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5165-5061","authenticated-orcid":false,"given":"Daniel Q.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1119-7799","authenticated-orcid":false,"given":"Ramon","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"McClain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Mellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tincopa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9018-7988","authenticated-orcid":false,"given":"Mack C.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0620-9705","authenticated-orcid":false,"given":"Mary E.","family":"Rinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0544-5610","authenticated-orcid":false,"given":"Shiv K.","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7620-573X","authenticated-orcid":false,"given":"Vijay H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyongyi","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7501-2191","authenticated-orcid":false,"given":"Meena B.","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7284-8754","authenticated-orcid":false,"given":"Lorenzo","family":"Leggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7888-1165","authenticated-orcid":false,"given":"Patrick S.","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9598-4932","authenticated-orcid":false,"given":"Aleksander","family":"Krag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8682-5748","authenticated-orcid":false,"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Arrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8561-396X","authenticated-orcid":false,"given":"Juan Pablo","family":"Arab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9518-0088","authenticated-orcid":false,"given":"Quentin M.","family":"Anstee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Mathurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-9991","authenticated-orcid":false,"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"1120_CR1","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1053\/j.gastro.2016.03.005","volume":"150","author":"Z Younossi","year":"2016","unstructured":"Younossi, Z. & Henry, L. Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology 150, 1778\u20131785 (2016).","journal-title":"Gastroenterology"},{"key":"1120_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","volume":"392","author":"MG Griswold","year":"2018","unstructured":"Griswold, M. G. et al. Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet 392, 1015\u20131035 (2018).","journal-title":"Lancet"},{"key":"1120_CR3","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78, 1966\u20131986 (2023).","journal-title":"Hepatology"},{"key":"1120_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.02.006","author":"GJ Kit Ho","year":"2025","unstructured":"Kit Ho, G. J. et al. High global prevalence of steatotic liver disease and associated subtypes: a meta-analysis. Clin. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2025.02.006 (2025).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1120_CR5","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","volume":"403","author":"GBD 2021 Risk Factors Collaborators","year":"2024","unstructured":"GBD 2021 Risk Factors Collaborators Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of disease study 2021. Lancet 403, 2162\u20132203 (2024).","journal-title":"Lancet"},{"key":"1120_CR6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S2468-1253(24)00427-8","volume":"10","author":"A Krag","year":"2025","unstructured":"Krag, A., Torp, N., Younossi, Z. M. & Israelsen, M. Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD. Lancet Gastroenterol. Hepatol. 10, 282\u2013284 (2025).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1120_CR7","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","volume":"404","author":"M Israelsen","year":"2024","unstructured":"Israelsen, M., Francque, S., Tsochatzis, E. A. & Krag, A. Steatotic liver disease. Lancet 404, 1761\u20131778 (2024).","journal-title":"Lancet"},{"key":"1120_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jhep.2025.04.035","volume":"83","author":"LA D\u00edaz","year":"2025","unstructured":"D\u00edaz, L. A. et al. High inherited risk predicts age-associated increases in fibrosis in patients with MASLD. J. Hepatol.\u00a083, 849\u2013859 (2025).","journal-title":"J. Hepatol."},{"key":"1120_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70017","volume":"45","author":"G Ayares","year":"2025","unstructured":"Ayares, G. et al. MetALD: new perspectives on an old overlooked disease. Liver Int. 45, e70017 (2025).","journal-title":"Liver Int."},{"key":"1120_CR10","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jhep.2024.11.028","volume":"82","author":"JP Arab","year":"2025","unstructured":"Arab, J. P. et al. Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease. J. Hepatol. 82, 744\u2013756 (2025).","journal-title":"J. Hepatol."},{"key":"1120_CR11","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jhep.2022.04.040","volume":"77","author":"K Staufer","year":"2022","unstructured":"Staufer, K. et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J. Hepatol. 77, 918\u2013930 (2022).","journal-title":"J. Hepatol."},{"key":"1120_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/JAN.0000000000000384","volume":"32","author":"LA Farinelli","year":"2021","unstructured":"Farinelli, L. A., Piacentino, D., Browning, B. D., Brewer, B. B. & Leggio, L. Cardiovascular consequences of excessive alcohol drinking via electrocardiogram: a systematic review. J. Addict. Nurs. 32, 39\u201345 (2021).","journal-title":"J. Addict. Nurs."},{"key":"1120_CR13","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41575-023-00822-y","volume":"20","author":"LA D\u00edaz","year":"2023","unstructured":"D\u00edaz, L. A., Arab, J. P., Louvet, A., Bataller, R. & Arrese, M. The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 20, 764\u2013783 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1120_CR14","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","volume":"81","author":"D Marti-Aguado","year":"2024","unstructured":"Marti-Aguado, D. et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J. Hepatol.\u00a081, 930\u2013940 (2024).","journal-title":"J. Hepatol."},{"key":"1120_CR15","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S2468-1253(23)00206-6","volume":"8","author":"M Israelsen","year":"2023","unstructured":"Israelsen, M., Torp, N., Johansen, S., Thiele, M. & Krag, A. MetALD: new opportunities to understand the role of alcohol in steatotic liver disease. Lancet Gastroenterol. Hepatol. 8, 866\u2013868 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1120_CR16","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.cgh.2018.01.026","volume":"16","author":"V Ajmera","year":"2018","unstructured":"Ajmera, V. et al. Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis. Clin. Gastroenterol. Hepatol. 16, 1511\u20131520.e5 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1120_CR17","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/hep.30864","volume":"71","author":"F \u00c5berg","year":"2020","unstructured":"\u00c5berg, F. et al. Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts. Hepatology 71, 835\u2013848 (2020).","journal-title":"Hepatology"},{"key":"1120_CR18","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/dar.13286","volume":"40","author":"J Rehm","year":"2021","unstructured":"Rehm, J. et al. The role of alcohol use in the aetiology and progression of liver disease: a narrative review and a quantification. Drug Alcohol Rev. 40, 1377\u20131386 (2021).","journal-title":"Drug Alcohol Rev."},{"key":"1120_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/HEP.0000000000000925","volume":"81","author":"M Kwak","year":"2024","unstructured":"Kwak, M. et al. MASLD\/MetALD and mortality in individuals with any cardio-metabolic risk factor: a population based study with 26.7 years of follow-up. Hepatology\u00a081, 228\u2013237 (2024).","journal-title":"Hepatology"},{"key":"1120_CR20","doi-asserted-by":"publisher","first-page":"410","DOI":"10.14309\/ajg.0000000000002920","volume":"120","author":"B Yun","year":"2024","unstructured":"Yun, B. et al. Liver cancer risk across metabolic dysfunction-associated steatotic liver disease and\/or alcohol: a nationwide study. Am. J. Gastroenterol.\u00a0120, 410\u2013419 (2024).","journal-title":"Am. J. Gastroenterol."},{"key":"1120_CR21","doi-asserted-by":"publisher","first-page":"155800","DOI":"10.1016\/j.metabol.2024.155800","volume":"153","author":"HJ Choe","year":"2024","unstructured":"Choe, H. J., Moon, J. H., Kim, W., Koo, B. K. & Cho, N. H. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up. Metabolism 153, 155800 (2024).","journal-title":"Metabolism"},{"key":"1120_CR22","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1111\/jgh.16726","volume":"39","author":"MB Aboona","year":"2024","unstructured":"Aboona, M. B. et al. Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake. J. Gastroenterol. Hepatol. 39, 2456\u20132463 (2024).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1120_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s43856-024-00649-x","volume":"4","author":"LA D\u00edaz","year":"2024","unstructured":"D\u00edaz, L. A. et al. Disparities in steatosis prevalence in the United States by race or ethnicity according to the 2023 criteria. Commun. Med. 4, 219 (2024).","journal-title":"Commun. Med."},{"key":"1120_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1259\/bjr\/38447238","volume":"85","author":"A Shuster","year":"2012","unstructured":"Shuster, A., Patlas, M., Pinthus, J. H. & Mourtzakis, M. The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br. J. Radiol. 85, 1\u201310 (2012).","journal-title":"Br. J. Radiol."},{"key":"1120_CR25","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.amjmed.2018.02.002","volume":"131","author":"JJ Lee","year":"2018","unstructured":"Lee, J. J. et al. Visceral and intrahepatic fat are associated with cardiometabolic risk factors above other ectopic fat depots: the Framingham Heart Study. Am. J. Med. 131, 684\u2013692.e12 (2018).","journal-title":"Am. J. Med."},{"key":"1120_CR26","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1161\/CIR.0b013e318233bc6a","volume":"124","author":"M-A Cornier","year":"2011","unstructured":"Cornier, M.-A. et al. Assessing adiposity: a scientific statement from the American Heart Association. Circulation 124, 1996\u20132019 (2011).","journal-title":"Circulation"},{"key":"1120_CR27","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/j.1467-789X.2011.00879.x","volume":"12","author":"S Czernichow","year":"2011","unstructured":"Czernichow, S., Kengne, A.-P., Stamatakis, E., Hamer, M. & Batty, G. D. Body mass index, waist circumference and waist-hip ratio: which is the better discriminator of cardiovascular disease mortality risk?: evidence from an individual-participant meta-analysis of 82 864 participants from nine cohort studies. Obes. Rev. 12, 680\u2013687 (2011).","journal-title":"Obes. Rev."},{"key":"1120_CR28","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.cgh.2017.02.040","volume":"15","author":"A Andreasson","year":"2017","unstructured":"Andreasson, A., Carlsson, A. C., \u00d6nnerhag, K. & Hagstr\u00f6m, H. Waist\/hip ratio better predicts development of severe liver disease within 20 years than body mass index: a population-based cohort study. Clin. Gastroenterol. Hepatol. 15, 1294\u20131301.e2 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1120_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s43856-023-00353-2","volume":"3","author":"F \u00c5berg","year":"2023","unstructured":"\u00c5berg, F. et al. Waist-hip ratio is superior to BMI in predicting liver-related outcomes and synergizes with harmful alcohol use. Commun. Med. 3, 119 (2023).","journal-title":"Commun. Med."},{"key":"1120_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-01134-z","volume":"22","author":"Y Xie","year":"2022","unstructured":"Xie, Y., Kong, W., Wang, X. & Wu, Z. Association of glycated hemoglobin with non-alcoholic fatty liver disease patients and the severity of liver steatosis and fibrosis measured by transient elastography in adults without diabetes. BMC Endocr. Disord. 22, 220 (2022).","journal-title":"BMC Endocr. Disord."},{"key":"1120_CR31","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/hep.31806","volume":"74","author":"A-S Alexopoulos","year":"2021","unstructured":"Alexopoulos, A.-S. et al. Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease. Hepatology 74, 1220\u20131233 (2021).","journal-title":"Hepatology"},{"key":"1120_CR32","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.numecd.2022.12.010","volume":"33","author":"S Colosimo","year":"2023","unstructured":"Colosimo, S., Tan, G. D., Petroni, M. L., Marchesini, G. & Tomlinson, J. W. Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent. Nutr. Metab. Cardiovasc. Dis. 33, 640\u2013648 (2023).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"1120_CR33","doi-asserted-by":"publisher","first-page":"8623","DOI":"10.3390\/ijms23158623","volume":"23","author":"K-H Cho","year":"2022","unstructured":"Cho, K.-H., Nam, H.-S., Kang, D.-J., Park, M.-H. & Kim, J.-H. Long-term alcohol consumption caused a significant decrease in serum high-density lipoprotein (HDL)-cholesterol and apolipoprotein A-I with the atherogenic changes of HDL in middle-aged Korean women. Int. J. Mol. Sci. 23, 8623 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1120_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2016.12.008","volume":"257","author":"Y Tabara","year":"2017","unstructured":"Tabara, Y. et al. The causal effects of alcohol on lipoprotein subfraction and triglyceride levels using a Mendelian randomization analysis: the Nagahama Study. Atherosclerosis 257, 22\u201328 (2017).","journal-title":"Atherosclerosis"},{"key":"1120_CR35","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S2468-1253(24)00380-7","volume":"10","author":"LA D\u00edaz","year":"2025","unstructured":"D\u00edaz, L. A. et al. Management of alcohol use disorder: a gastroenterology and hepatology-focused perspective. Lancet Gastroenterol. Hepatol.\u00a010, 475\u2013490 (2025).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1120_CR36","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/add.13341","volume":"111","author":"A Kalinowski","year":"2016","unstructured":"Kalinowski, A. & Humphreys, K. Governmental standard drink definitions and low-risk alcohol consumption guidelines in 37 countries. Addiction 111, 1293\u20131298 (2016).","journal-title":"Addiction"},{"key":"1120_CR37","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jhep.2022.11.013","volume":"78","author":"A Louvet","year":"2023","unstructured":"Louvet, A. et al. Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort. J. Hepatol. 78, 501\u2013512 (2023).","journal-title":"J. Hepatol."},{"key":"1120_CR38","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41572-022-00406-1","volume":"8","author":"J MacKillop","year":"2022","unstructured":"MacKillop, J. et al. Hazardous drinking and alcohol use disorders. Nat. Rev. Dis. Primers 8, 80 (2022).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1120_CR39","doi-asserted-by":"crossref","unstructured":"Saitz, R. (ed.) Addressing Unhealthy Alcohol Use in Primary Care (Springer, 2012).","DOI":"10.1007\/978-1-4614-4779-5"},{"key":"1120_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261292","volume":"16","author":"K Tevik","year":"2021","unstructured":"Tevik, K., Bergh, S., Selb\u00e6k, G., Johannessen, A. & Helvik, A.-S. A systematic review of self-report measures used in epidemiological studies to assess alcohol consumption among older adults. PLoS ONE 16, e0261292 (2021).","journal-title":"PLoS ONE"},{"key":"1120_CR41","unstructured":"Babor, T. F., Higgins-Biddle, J. C., Saunders, J. B., Monteiro, M. G. AUDIT: The Alcohol Use Disorders Identification Test (WHO, 2001)."},{"key":"1120_CR42","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1037\/0022-006X.68.1.134","volume":"68","author":"W Fals-Stewart","year":"2000","unstructured":"Fals-Stewart, W., O\u2019Farrell, T. J., Freitas, T. T., McFarlin, S. K. & Rutigliano, P. The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J. Consult. Clin. Psychol. 68, 134\u2013144 (2000).","journal-title":"J. Consult. Clin. Psychol."},{"key":"1120_CR43","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1093\/aje\/kwh102","volume":"159","author":"IHM Friesema","year":"2004","unstructured":"Friesema, I. H. M. et al. Measurement of lifetime alcohol intake: utility of a self-administered questionnaire. Am. J. Epidemiol. 159, 809\u2013817 (2004).","journal-title":"Am. J. Epidemiol."},{"key":"1120_CR44","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s40429-021-00402-7","volume":"8","author":"JC Harris","year":"2021","unstructured":"Harris, J. C., Leggio, L. & Farokhnia, M. Blood biomarkers of alcohol use: a scoping review. Curr. Addict. Rep. 8, 500\u2013508 (2021).","journal-title":"Curr. Addict. Rep."},{"key":"1120_CR45","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41746-024-01089-6","volume":"7","author":"H Pod\u00e9us","year":"2024","unstructured":"Pod\u00e9us, H. et al. A physiologically-based digital twin for alcohol consumption \u2014 predicting real-life drinking responses and long-term plasma PEth. npj Digit. Med. 7, 112 (2024).","journal-title":"npj Digit. Med."},{"key":"1120_CR46","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/acer.14611","volume":"45","author":"JA Hahn","year":"2021","unstructured":"Hahn, J. A. et al. Factors associated with phosphatidylethanol (PEth) sensitivity for detecting unhealthy alcohol use: an individual patient data meta-analysis. Alcohol. Clin. Exp. Res. 45, 1166\u20131187 (2021).","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"1120_CR47","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/bcpt.13814","volume":"132","author":"A \u00c5rving","year":"2023","unstructured":"\u00c5rving, A., Hilberg, T., Sovershaev, M., Bogstrand, S. T. & H\u00f8iseth, G. Falsely low phosphatidylethanol may be associated with biomarkers of haemolytic disease. Basic Clin. Pharmacol. Toxicol. 132, 223\u2013230 (2023).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"1120_CR48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cca.2021.11.013","volume":"524","author":"N Aboutara","year":"2022","unstructured":"Aboutara, N. et al. Phosphatidylethanol in patients with liver diseases of different etiologies: analysis of six homologues and comparison with other alcohol markers. Clin. Chim. Acta 524, 171\u2013178 (2022).","journal-title":"Clin. Chim. Acta"},{"key":"1120_CR49","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1111\/acer.12442","volume":"38","author":"SH Stewart","year":"2014","unstructured":"Stewart, S. H., Koch, D. G., Willner, I. R., Anton, R. F. & Reuben, A. Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease. Alcohol. Clin. Exp. Res. 38, 1706\u20131711 (2014).","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"1120_CR50","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.33182","volume":"6","author":"JA Hahn","year":"2023","unstructured":"Hahn, J. A., Fatch, R., Barnett, N. P. & Marcus, G. M. Phosphatidylethanol vs transdermal alcohol monitoring for detecting alcohol consumption among adults. JAMA Netw. Open 6, e2333182 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1120_CR51","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1080\/00365513.2023.2253734","volume":"83","author":"A Helander","year":"2023","unstructured":"Helander, A. & Hansson, T. The alcohol biomarker phosphatidylethanol (PEth) \u2014 test performance and experiences from routine analysis and external quality assessment. Scand. J. Clin. Lab. Invest. 83, 424\u2013431 (2023).","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"1120_CR52","doi-asserted-by":"publisher","first-page":"agae040","DOI":"10.1093\/alcalc\/agae040","volume":"59","author":"T Finanger","year":"2024","unstructured":"Finanger, T. et al. Relationship between alcohol intake based on daily smartphone-reported consumption and PEth concentrations in healthy volunteers. Alcohol Alcohol. 59, agae040 (2024).","journal-title":"Alcohol Alcohol."},{"key":"1120_CR53","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/apt.18506","volume":"61","author":"F Tavaglione","year":"2025","unstructured":"Tavaglione, F. et al. Head-to-head comparison between phosphatidylethanol versus indirect alcohol biomarkers for diagnosis of MetALD versus MASLD: a prospective study. Aliment. Pharmacol. Ther.\u00a061, 1043\u20131054 (2025).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1120_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.04.019","author":"J Vaz","year":"2025","unstructured":"Vaz, J. et al. Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes. J. Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2025.04.019 (2025).","journal-title":"J. Hepatol."},{"key":"1120_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.05.030","author":"F Tavaglione","year":"2025","unstructured":"Tavaglione, F. et al. Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification. J. Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2025.05.030 (2025).","journal-title":"J. Hepatol."},{"key":"1120_CR56","doi-asserted-by":"publisher","first-page":"101200","DOI":"10.1016\/j.jhepr.2024.101200","volume":"7","author":"ED Hansen","year":"2024","unstructured":"Hansen, E. D. et al. Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake. JHEP Rep. 7, 101200 (2024).","journal-title":"JHEP Rep."},{"key":"1120_CR57","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.07.007","author":"R Loomba","year":"2025","unstructured":"Loomba, R., Hagstr\u00f6m, H. & D\u00edaz, L. A. Emerging role of phosphatidylethanol testing in clinical practice for the identification of steatotic liver disease subtypes: is this the new standard? Gastroenterology https:\/\/doi.org\/10.1053\/j.gastro.2025.07.007 (2025).","journal-title":"Gastroenterology"},{"key":"1120_CR58","unstructured":"US Food and Drug Administration. Noncirrhotic Nonalcoholic Steatohepatitis with Liver Fibrosis: Developing Drugs for Treatment: Guidance for Industry (FDA, 2018)."},{"key":"1120_CR59","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","volume":"9","author":"M Israelsen","year":"2024","unstructured":"Israelsen, M. et al. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol. Hepatol. 9, 218\u2013228 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1120_CR60","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/jat\/bkaa082","volume":"45","author":"RB Skr\u00e5stad","year":"2021","unstructured":"Skr\u00e5stad, R. B., Spigset, O., Aamo, T. O. & Andreassen, T. N. Stability of phosphatidylethanol 16:0\/18:1 in freshly drawn, authentic samples from healthy volunteers. J. Anal. Toxicol. 45, 417\u2013421 (2021).","journal-title":"J. Anal. Toxicol."},{"key":"1120_CR61","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1373\/clinchem.2008.120923","volume":"55","author":"A Helander","year":"2009","unstructured":"Helander, A. & Zheng, Y. Molecular species of the alcohol biomarker phosphatidylethanol in human blood measured by LC-MS. Clin. Chem. 55, 1395\u20131405 (2009).","journal-title":"Clin. Chem."},{"key":"1120_CR62","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00414-017-1626-2","volume":"131","author":"R Boll","year":"2017","unstructured":"Boll, R., Johnson, T., Kaaks, R., K\u00fchn, T. & Skopp, G. Is it possible to detect PEth 16:0\/18:1 and PEth 18:1\/18:1 in red blood cells after 20 years of storage in liquid nitrogen? Int. J. Leg. Med. 131, 1291\u20131297 (2017).","journal-title":"Int. J. Leg. Med."},{"key":"1120_CR63","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.clinms.2018.12.002","volume":"11","author":"H-\u00c5 Lakso","year":"2019","unstructured":"Lakso, H. -\u00c5, Wuolikainen, A., Sundkvist, A., Johansson, I. & Marklund, S. L. Long-term stability of the alcohol consumption biomarker phosphatidylethanol in erythrocytes at \u221280 \u00b0C. Clin. Mass. Spectrom. 11, 37\u201341 (2019).","journal-title":"Clin. Mass. Spectrom."},{"key":"1120_CR64","doi-asserted-by":"publisher","first-page":"101433","DOI":"10.1016\/j.jhepr.2025.101433","volume":"7","author":"BTK Vanlerberghe","year":"2025","unstructured":"Vanlerberghe, B. T. K. et al. Phosphatidylethanol and ethyl glucuronide to categorize alcohol consumption in alcohol-related cirrhosis. JHEP Rep. 7, 101433 (2025).","journal-title":"JHEP Rep."},{"key":"1120_CR65","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/alcalc\/agad015","volume":"58","author":"RB Skr\u00e5stad","year":"2023","unstructured":"Skr\u00e5stad, R. B. et al. Quantifying alcohol consumption in the general population by analysing phosphatidylethanol concentrations in whole blood: results from 24,574 subjects included in the HUNT4 study. Alcohol Alcohol. 58, 258\u2013265 (2023).","journal-title":"Alcohol Alcohol."},{"key":"1120_CR66","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/alcalc\/agy031","volume":"53","author":"ID Munsterman","year":"2018","unstructured":"Munsterman, I. D. et al. Biochemical effects on the liver of 1 month of alcohol abstinence in moderate alcohol consumers. Alcohol Alcohol. 53, 435\u2013438 (2018).","journal-title":"Alcohol Alcohol."},{"key":"1120_CR67","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020673","volume":"8","author":"G Mehta","year":"2018","unstructured":"Mehta, G. et al. Short-term abstinence from alcohol and changes in cardiovascular risk factors, liver function tests and cancer-related growth factors: a prospective observational study. BMJ Open\u00a08, e020673 (2018).","journal-title":"BMJ Open"},{"key":"1120_CR68","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0168-8278(01)00228-8","volume":"36","author":"BJ Veldt","year":"2002","unstructured":"Veldt, B. J. et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J. Hepatol. 36, 93\u201398 (2002).","journal-title":"J. Hepatol."},{"key":"1120_CR69","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2967\/jnumed.119.228825","volume":"61","author":"J Ceccarini","year":"2020","unstructured":"Ceccarini, J. et al. Recovery of decreased metabotropic glutamate receptor 5 availability in abstinent alcohol-dependent patients. J. Nucl. Med. 61, 256\u2013262 (2020).","journal-title":"J. Nucl. Med."},{"key":"1120_CR70","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ijpsycho.2022.05.015","volume":"177","author":"A Mart\u00ednez-Maldonado","year":"2022","unstructured":"Mart\u00ednez-Maldonado, A., Rubio, G., Sion, A. & Jurado-Barba, R. Brain oscillatory functioning after long-term alcohol abstinence. Int. J. Psychophysiol. 177, 240\u2013248 (2022).","journal-title":"Int. J. Psychophysiol."},{"key":"1120_CR71","doi-asserted-by":"publisher","first-page":"109695","DOI":"10.1016\/j.drugalcdep.2022.109695","volume":"242","author":"BK Linn","year":"2023","unstructured":"Linn, B. K. et al. Relationship of negative emotionality, NIAAA recovery, and 3- and 6-month drinking outcomes among adults in treatment for alcohol use disorder. Drug Alcohol Depend. 242, 109695 (2023).","journal-title":"Drug Alcohol Depend."},{"key":"1120_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0296043","volume":"19","author":"A Powell","year":"2024","unstructured":"Powell, A., Sumnall, H., Smith, J., Kuiper, R. & Montgomery, C. Recovery of neuropsychological function following abstinence from alcohol in adults diagnosed with an alcohol use disorder: systematic review of longitudinal studies. PLoS ONE 19, e0296043 (2024).","journal-title":"PLoS ONE"},{"key":"1120_CR73","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jhep.2022.07.004","volume":"77","author":"AM Allen","year":"2022","unstructured":"Allen, A. M. et al. Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design. J. Hepatol. 77, 1237\u20131245 (2022).","journal-title":"J. Hepatol."},{"key":"1120_CR74","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/hep.29797","volume":"68","author":"C Caussy","year":"2018","unstructured":"Caussy, C., Reeder, S. B., Sirlin, C. B. & Loomba, R. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology 68, 763\u2013772 (2018).","journal-title":"Hepatology"},{"key":"1120_CR75","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJM200102153440706","volume":"344","author":"AA Bravo","year":"2001","unstructured":"Bravo, A. A., Sheth, S. G. & Chopra, S. Liver biopsy. N. Engl. J. Med. 344, 495\u2013500 (2001).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR76","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hep.22742","volume":"49","author":"DC Rockey","year":"2009","unstructured":"Rockey, D. C. et al. Liver biopsy. Hepatology 49, 1017\u20131044 (2009).","journal-title":"Hepatology"},{"key":"1120_CR77","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/MOG.0000000000000621","volume":"36","author":"A Khalifa","year":"2020","unstructured":"Khalifa, A. & Rockey, D. C. The utility of liver biopsy in 2020. Curr. Opin. Gastroenterol. 36, 184\u2013191 (2020).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"1120_CR78","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","volume":"128","author":"V Ratziu","year":"2005","unstructured":"Ratziu, V. et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128, 1898\u20131906 (2005).","journal-title":"Gastroenterology"},{"key":"1120_CR79","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2023.10.015","volume":"80","author":"V Ratziu","year":"2024","unstructured":"Ratziu, V. et al. Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions. J. Hepatol. 80, 335\u2013351 (2024).","journal-title":"J. Hepatol."},{"key":"1120_CR80","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","volume":"15","author":"V Wong","year":"2018","unstructured":"Wong, V., Adams, L., de L\u00e9dinghen, V., Wong, G. & Sookoian, S. Noninvasive biomarkers in NAFLD and NASH \u2014 current progress and future promise. Nat. Rev. Gastroenterol. Hepatol. 15, 461\u2013478 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1120_CR81","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.cgh.2014.11.027","volume":"13","author":"SC Lin","year":"2015","unstructured":"Lin, S. C. et al. Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat using a new quantitative ultrasound technique. Clin. Gastroenterol. Hepatol. 13, 1337\u20131345.e6 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1120_CR82","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1053\/j.gastro.2017.06.005","volume":"153","author":"MS Middleton","year":"2017","unstructured":"Middleton, M. S. et al. Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis. Gastroenterology 153, 753\u2013761 (2017).","journal-title":"Gastroenterology"},{"key":"1120_CR83","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1007\/s00330-019-06071-5","volume":"29","author":"Y Qu","year":"2019","unstructured":"Qu, Y., Li, M., Hamilton, G., Zhang, Y. N. & Song, B. Diagnostic accuracy of hepatic proton density fat fraction measured by magnetic resonance imaging for the evaluation of liver steatosis with histology as reference standard: a meta-analysis. Eur. Radiol. 29, 5180\u20135189 (2019).","journal-title":"Eur. Radiol."},{"key":"1120_CR84","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","volume":"19","author":"JG Stine","year":"2021","unstructured":"Stine, J. G. et al. Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 19, 2274\u20132283.e5 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1120_CR85","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/hep.26455","volume":"58","author":"M Noureddin","year":"2013","unstructured":"Noureddin, M. et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 58, 1930\u20131940 (2013).","journal-title":"Hepatology"},{"key":"1120_CR86","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/hep.27362","volume":"60","author":"R Loomba","year":"2014","unstructured":"Loomba, R. et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 60, 1920\u20131928 (2014).","journal-title":"Hepatology"},{"key":"1120_CR87","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jhep.2023.04.025","volume":"79","author":"J-X Liang","year":"2023","unstructured":"Liang, J.-X. et al. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. J. Hepatol. 79, 592\u2013604 (2023).","journal-title":"J. Hepatol."},{"key":"1120_CR88","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1053\/j.gastro.2022.06.073","volume":"163","author":"V Ajmera","year":"2022","unstructured":"Ajmera, V. et al. Liver stiffness on magnetic resonance elastography and the MEFIB Index and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants. Gastroenterology 163, 1079\u20131089.e5 (2022).","journal-title":"Gastroenterology"},{"key":"1120_CR89","unstructured":"Quantitative Imaging Biomarkers Alliance. QIBA Profile: Magnetic Resonance Elastography of the Liver. Stage 2: Consensus Profile (QIBA, 2018)."},{"key":"1120_CR90","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1148\/radiol.2017161398","volume":"285","author":"SD Serai","year":"2017","unstructured":"Serai, S. D. et al. Repeatability of MR elastography of liver: a meta-analysis. Radiology 285, 92\u2013100 (2017).","journal-title":"Radiology"},{"key":"1120_CR91","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","volume":"152","author":"CC Park","year":"2017","unstructured":"Park, C. C. et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology 152, 598\u2013607.e2 (2017).","journal-title":"Gastroenterology"},{"key":"1120_CR92","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","volume":"75","author":"EA Selvaraj","year":"2021","unstructured":"Selvaraj, E. A. et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. J. Hepatol. 75, 770\u2013785 (2021).","journal-title":"J. Hepatol."},{"key":"1120_CR93","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.cgh.2020.12.016","volume":"20","author":"K Imajo","year":"2022","unstructured":"Imajo, K. et al. Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 20, 908\u2013917.e11 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1120_CR94","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1007\/s00330-023-10441-5","volume":"34","author":"S Duman","year":"2024","unstructured":"Duman, S. et al. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone. Eur. Radiol. 34, 3882\u20133888 (2024).","journal-title":"Eur. Radiol."},{"key":"1120_CR95","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81, 492\u2013542 (2024).","journal-title":"J. Hepatol."},{"key":"1120_CR96","doi-asserted-by":"publisher","first-page":"101903","DOI":"10.1016\/j.aohep.2025.101903","volume":"30","author":"LA Diaz","year":"2025","unstructured":"Diaz, L. A. et al. Updated recommendations for the management of metabolic dysfunction-associated steatotic liver disease (MASLD) by the Latin American Working Group. Ann. Hepatol. 30, 101903 (2025).","journal-title":"Ann. Hepatol."},{"key":"1120_CR97","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera, L., Friedrich-Rust, M. & Loomba, R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156, 1264\u20131281.e4 (2019).","journal-title":"Gastroenterology"},{"key":"1120_CR98","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","volume":"17","author":"MS Siddiqui","year":"2019","unstructured":"Siddiqui, M. S. et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 17, 156\u2013163.e2 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1120_CR99","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jhep.2018.11.025","volume":"70","author":"C Moreno","year":"2019","unstructured":"Moreno, C., Mueller, S. & Szabo, G. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. J. Hepatol. 70, 273\u2013283 (2019).","journal-title":"J. Hepatol."},{"key":"1120_CR100","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/hep.29489","volume":"67","author":"R Vuppalanchi","year":"2018","unstructured":"Vuppalanchi, R. et al. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology 67, 134\u2013144 (2018).","journal-title":"Hepatology"},{"key":"1120_CR101","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jama.2024.1447","volume":"331","author":"H Lin","year":"2024","unstructured":"Lin, H. et al. Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease. JAMA 331, 1287\u20131297 (2024).","journal-title":"JAMA"},{"key":"1120_CR102","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.jhep.2024.05.021","volume":"81","author":"M Papatheodoridi","year":"2024","unstructured":"Papatheodoridi, M. et al. Agile scores in MASLD and ALD: external validation and their utility in clinical algorithms. J. Hepatol. 81, 590\u2013599 (2024).","journal-title":"J. Hepatol."},{"key":"1120_CR103","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","volume":"73","author":"Y Vali","year":"2020","unstructured":"Vali, Y. et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J. Hepatol. 73, 252\u2013262 (2020).","journal-title":"J. Hepatol."},{"key":"1120_CR104","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.23923","volume":"4","author":"ZM Younossi","year":"2021","unstructured":"Younossi, Z. M. et al. Performance of the enhanced liver fibrosis test to estimate advanced fibrosis among patients with nonalcoholic fatty liver disease. JAMA Netw. Open 4, e2123923 (2021).","journal-title":"JAMA Netw. Open"},{"key":"1120_CR105","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","volume":"8","author":"Y Vali","year":"2023","unstructured":"Vali, Y. et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol. Hepatol. 8, 714\u2013725 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1120_CR106","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1053\/j.gastro.2018.01.005","volume":"154","author":"M Thiele","year":"2018","unstructured":"Thiele, M. et al. Accuracy of the enhanced liver fibrosis test vs fibrotest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease. Gastroenterology 154, 1369\u20131379 (2018).","journal-title":"Gastroenterology"},{"key":"1120_CR107","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.cgh.2020.06.070","volume":"19","author":"VS Are","year":"2021","unstructured":"Are, V. S., Vuppalanchi, R., Vilar-Gomez, E. & Chalasani, N. Enhanced liver fibrosis score can be used to predict liver-related events in patients with nonalcoholic steatohepatitis and compensated cirrhosis. Clin. Gastroenterol. Hepatol. 19, 1292\u20131293.e3 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1120_CR108","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/hep.30842","volume":"70","author":"QM Anstee","year":"2019","unstructured":"Anstee, Q. M. et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials. Hepatology 70, 1521\u20131530 (2019).","journal-title":"Hepatology"},{"key":"1120_CR109","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jpeds.2021.08.012","volume":"239","author":"S Gawrieh","year":"2021","unstructured":"Gawrieh, S. et al. Relationship of enhanced liver fibrosis score with pediatric nonalcoholic fatty liver disease histology and response to vitamin E or metformin. J. Pediatr. 239, 161\u2013167.e5 (2021).","journal-title":"J. Pediatr."},{"key":"1120_CR110","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/hep.27678","volume":"61","author":"AJ Sanyal","year":"2015","unstructured":"Sanyal, A. J. et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases\u2013US Food and Drug Administration Joint Workshop. Hepatology 61, 1392\u20131405 (2015).","journal-title":"Hepatology"},{"key":"1120_CR111","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1053\/j.gastro.2021.10.051","volume":"162","author":"R Loomba","year":"2022","unstructured":"Loomba, R., Ratziu, V., Harrison, S. A. & NASH Clinical Trial Design International Working Group. Expert panel review to compare FDA and EMA guidance on drug development and endpoints in nonalcoholic steatohepatitis. Gastroenterology 162, 680\u2013688 (2022).","journal-title":"Gastroenterology"},{"key":"1120_CR112","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jhep.2019.04.019","volume":"71","author":"ME Rinella","year":"2019","unstructured":"Rinella, M. E., Tacke, F., Sanyal, A. J., Anstee, Q. M. & participants of the AASLD\/EASL Workshop. Report on the AASLD\/EASL joint workshop on clinical trial endpoints in NAFLD. J. Hepatol. 71, 823\u2013833 (2019).","journal-title":"J. Hepatol."},{"key":"1120_CR113","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1472-8206.2010.00865.x","volume":"25","author":"M Domanski","year":"2011","unstructured":"Domanski, M. et al. Surrogate endpoints in randomized cardiovascular clinical trials. Fundam. Clin. Pharmacol. 25, 411\u2013413 (2011).","journal-title":"Fundam. Clin. Pharmacol."},{"key":"1120_CR114","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1001\/jamainternmed.2018.8351","volume":"179","author":"EY Chen","year":"2019","unstructured":"Chen, E. Y., Joshi, S. K., Tran, A. & Prasad, V. Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials. JAMA Intern. Med. 179, 642\u2013647 (2019).","journal-title":"JAMA Intern. Med."},{"key":"1120_CR115","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jtho.2021.01.1616","volume":"16","author":"F-S Ou","year":"2021","unstructured":"Ou, F.-S., Michiels, S., Shyr, Y., Adjei, A. A. & Oberg, A. L. Biomarker discovery and validation: statistical considerations. J. Thorac. Oncol. 16, 537\u2013545 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"1120_CR116","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and Other Tools) Resource (FDA, 2016)."},{"key":"1120_CR117","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal, A. J. et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N. Engl. J. Med. 385, 1559\u20131569 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR118","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/liv.15526","volume":"43","author":"MD Theodoreson","year":"2023","unstructured":"Theodoreson, M. D. et al. Extra-hepatic morbidity and mortality in alcohol-related liver disease: systematic review and meta-analysis. Liver Int. 43, 763\u2013772 (2023).","journal-title":"Liver Int."},{"key":"1120_CR119","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/hep.30866","volume":"71","author":"DW Crabb","year":"2020","unstructured":"Crabb, D. W., Im, G. Y., Szabo, G., Mellinger, J. L. & Lucey, M. R. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 71, 306\u2013333 (2020).","journal-title":"Hepatology"},{"key":"1120_CR120","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000718","volume":"9","author":"LA D\u00edaz","year":"2025","unstructured":"D\u00edaz, L. A. et al. Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD). Hepatol. Commun. 9, e0718 (2025).","journal-title":"Hepatol. Commun."},{"key":"1120_CR121","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis, R. et al. Baveno VII \u2013 renewing consensus in portal hypertension. J. Hepatol. 76, 959\u2013974 (2022).","journal-title":"J. Hepatol."},{"key":"1120_CR122","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1053\/j.gastro.2021.08.050","volume":"161","author":"WR Kim","year":"2021","unstructured":"Kim, W. R. et al. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology\u00a0161, 1887\u20131895.e4 (2021).","journal-title":"Gastroenterology"},{"key":"1120_CR123","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/13543784.2022.2032640","volume":"31","author":"P Aggarwal","year":"2022","unstructured":"Aggarwal, P., Noureddin, M., Harrison, S., Jeannin, S. & Alkhouri, N. Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials. Expert Opin. Investig. Drugs 31, 163\u2013172 (2022).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1120_CR124","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1038\/s41591-024-03223-z","volume":"30","author":"F Zannad","year":"2024","unstructured":"Zannad, F., Sanyal, A. J., Butler, J., Miller, V. & Harrison, S. A. Integrating liver endpoints in clinical trials of cardiovascular and kidney disease. Nat. Med. 30, 2423\u20132431 (2024).","journal-title":"Nat. Med."},{"key":"1120_CR125","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","volume":"165","author":"JJ Wattacheril","year":"2023","unstructured":"Wattacheril, J. J., Abdelmalek, M. F., Lim, J. K. & Sanyal, A. J. AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review. Gastroenterology 165, 1080\u20131088 (2023).","journal-title":"Gastroenterology"},{"key":"1120_CR126","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jhep.2024.03.023","volume":"81","author":"L Castera","year":"2024","unstructured":"Castera, L. et al. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes. J. Hepatol. 81, 195\u2013206 (2024).","journal-title":"J. Hepatol."},{"key":"1120_CR127","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1111\/j.1530-0277.2012.01737.x","volume":"36","author":"J-B Trabut","year":"2012","unstructured":"Trabut, J.-B. et al. Rapid decline of liver stiffness following alcohol withdrawal in heavy drinkers. Alcohol. Clin. Exp. Res. 36, 1407\u20131411 (2012).","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"1120_CR128","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/alcalc\/agw053","volume":"52","author":"E Gianni","year":"2017","unstructured":"Gianni, E. et al. Prospective evaluation of liver stiffness using transient elastography in alcoholic patients following abstinence. Alcohol Alcohol. 52, 42\u201347 (2017).","journal-title":"Alcohol Alcohol."},{"key":"1120_CR129","doi-asserted-by":"publisher","first-page":"916","DOI":"10.14309\/ajg.0000000000000153","volume":"114","author":"S Petta","year":"2019","unstructured":"Petta, S. et al. Impact of obesity and alanine aminotransferase levels on the diagnostic accuracy for advanced liver fibrosis of noninvasive tools in patients with nonalcoholic fatty liver disease. Am. J. Gastroenterol. 114, 916\u2013928 (2019).","journal-title":"Am. J. Gastroenterol."},{"key":"1120_CR130","doi-asserted-by":"publisher","first-page":"e2008","DOI":"10.1210\/clinem\/dgab933","volume":"107","author":"S Qadri","year":"2022","unstructured":"Qadri, S. et al. Obesity modifies the performance of fibrosis biomarkers in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 107, e2008\u2013e2020 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1120_CR131","doi-asserted-by":"publisher","first-page":"30","DOI":"10.14309\/ajg.0000000000002572","volume":"119","author":"LL Jophlin","year":"2024","unstructured":"Jophlin, L. L. et al. ACG clinical guideline: alcohol-associated liver disease. Am. J. Gastroenterol. 119, 30\u201354 (2024).","journal-title":"Am. J. Gastroenterol."},{"key":"1120_CR132","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S2468-1253(18)30124-9","volume":"3","author":"E Nguyen-Khac","year":"2018","unstructured":"Nguyen-Khac, E. et al. Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. Lancet Gastroenterol. Hepatol. 3, 614\u2013625 (2018).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1120_CR133","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3748\/wjg.v19.i4.516","volume":"19","author":"E Bardou-Jacquet","year":"2013","unstructured":"Bardou-Jacquet, E. et al. Effect of alcohol consumption on liver stiffness measured by transient elastography. World J. Gastroenterol. 19, 516\u2013522 (2013).","journal-title":"World J. Gastroenterol."},{"key":"1120_CR134","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/s41366-021-00881-8","volume":"45","author":"A Drolz","year":"2021","unstructured":"Drolz, A. et al. Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. Int. J. Obes. 45, 2197\u20132204 (2021).","journal-title":"Int. J. Obes."},{"key":"1120_CR135","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/hep.30974","volume":"71","author":"VH Ajmera","year":"2020","unstructured":"Ajmera, V. H. et al. Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease. Hepatology 71, 849\u2013860 (2020).","journal-title":"Hepatology"},{"key":"1120_CR136","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jhep.2022.09.021","volume":"78","author":"JM Peric\u00e0s","year":"2023","unstructured":"Peric\u00e0s, J. M. et al. Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons. J. Hepatol. 78, 442\u2013447 (2023).","journal-title":"J. Hepatol."},{"key":"1120_CR137","unstructured":"European Medicines Agency. Reflection Paper on Assessment of Cardiovascular Safety Profile of Medicinal Products (EMA, 2016)."},{"key":"1120_CR138","unstructured":"European Medicines Agency. Reflection Paper on Regulatory Requirements for the Development of Medicinal Products for Non-alcoholic Steatohepatitis (NASH) (EMA, 2024)."},{"key":"1120_CR139","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal, G. P. et al. Case definition and phenotype standardization in drug-induced liver injury. Clin. Pharmacol. Ther. 89, 806\u2013815 (2011).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1120_CR140","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41575-024-00936-x","volume":"21","author":"BP Lee","year":"2024","unstructured":"Lee, B. P. et al. Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel consensus statement. Nat. Rev. Gastroenterol. Hepatol. 21, 626\u2013645\u00a0(2024).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1120_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-79428-6","volume":"14","author":"HA Lee","year":"2024","unstructured":"Lee, H. A., Lee, H. A. & Kim, H. Y. Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms. Sci. Rep. 14, 28951 (2024).","journal-title":"Sci. Rep."},{"key":"1120_CR142","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1097\/01.ALC.0000093743.03049.80","volume":"27","author":"CS Lieber","year":"2003","unstructured":"Lieber, C. S. et al. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol. Clin. Exp. Res. 27, 1765\u20131772 (2003).","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"1120_CR143","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1097\/01.ALC.0000093744.12232.34","volume":"27","author":"CS Lieber","year":"2003","unstructured":"Lieber, C. S. et al. I. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease: effects on drinking behavior by nurse\/physician teams. Alcohol. Clin. Exp. Res. 27, 1757\u20131764 (2003).","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"1120_CR144","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1111\/acer.14670","volume":"45","author":"B Scherrer","year":"2021","unstructured":"Scherrer, B. et al. Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: a meta-regression analysis to develop an enrichment strategy. Alcohol. Clin. Exp. Res. 45, 1722\u20131734 (2021).","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"1120_CR145","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41575-021-00527-0","volume":"19","author":"JP Arab","year":"2022","unstructured":"Arab, J. P., Izzy, M., Leggio, L., Bataller, R. & Shah, V. H. Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation. Nat. Rev. Gastroenterol. Hepatol. 19, 45\u201359 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1120_CR146","doi-asserted-by":"publisher","first-page":"101165","DOI":"10.1016\/j.jhepr.2024.101165","volume":"6","author":"E Avitabile","year":"2024","unstructured":"Avitabile, E. et al. Liver fibrosis screening increases alcohol abstinence. JHEP Rep. 6, 101165 (2024).","journal-title":"JHEP Rep."},{"key":"1120_CR147","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.cgh.2023.12.018","volume":"22","author":"M Kjaergaard","year":"2024","unstructured":"Kjaergaard, M. et al. Screening for fibrosis promotes lifestyle changes: a prospective cohort study in 4796 individuals. Clin. Gastroenterol. Hepatol. 22, 1037\u20131047.e9 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1120_CR148","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jclinepi.2018.11.016","volume":"108","author":"J McCambridge","year":"2019","unstructured":"McCambridge, J., Wilson, A., Attia, J., Weaver, N. & Kypri, K. Randomized trial seeking to induce the Hawthorne effect found no evidence for any effect on self-reported alcohol consumption online. J. Clin. Epidemiol. 108, 102\u2013109 (2019).","journal-title":"J. Clin. Epidemiol."},{"key":"1120_CR149","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jsat.2017.11.002","volume":"84","author":"L Kramer Schmidt","year":"2018","unstructured":"Kramer Schmidt, L., Bojesen, A. B., Nielsen, A. S. & Andersen, K. Duration of therapy \u2013 does it matter?: A systematic review and meta-regression of the duration of psychosocial treatments for alcohol use disorder. J. Subst. Abus. Treat. 84, 57\u201367 (2018).","journal-title":"J. Subst. Abus. Treat."},{"key":"1120_CR150","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/ADM.0000000000001421","volume":"19","author":"H Gopalakrishna","year":"2025","unstructured":"Gopalakrishna, H. et al. Drug-induced liver injury due to medications for alcohol use disorder: results from the DILIN prospective study. J. Addict. Med. 19, 314\u2013321 (2025).","journal-title":"J. Addict. Med."},{"key":"1120_CR151","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.2023.19761","volume":"330","author":"M McPheeters","year":"2023","unstructured":"McPheeters, M. et al. Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis. JAMA 330, 1653\u20131665 (2023).","journal-title":"JAMA"},{"key":"1120_CR152","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77, 1797\u20131835 (2023).","journal-title":"Hepatology"},{"key":"1120_CR153","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez, E. et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149, 367\u201378.e5 (2015).","journal-title":"Gastroenterology"},{"key":"1120_CR154","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.tem.2024.05.009","volume":"6","author":"G Feng","year":"2025","unstructured":"Feng, G. et al. Recompensation in MASLD-related cirrhosis via metabolic bariatric surgery. Trends Endocrinol. Metab.\u00a06, 118\u2013132 (2025).","journal-title":"Trends Endocrinol. Metab."},{"key":"1120_CR155","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1007\/s11695-023-06490-w","volume":"33","author":"E Alvarado-Tapias","year":"2023","unstructured":"Alvarado-Tapias, E. et al. Bariatric surgery is associated with alcohol-related liver disease and psychiatric disorders associated with AUD. Obes. Surg. 33, 1494\u20131505 (2023).","journal-title":"Obes. Surg."},{"key":"1120_CR156","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1007\/s00464-021-08329-w","volume":"35","author":"DI Athanasiadis","year":"2021","unstructured":"Athanasiadis, D. I., Martin, A., Kapsampelis, P., Monfared, S. & Stefanidis, D. Factors associated with weight regain post-bariatric surgery: a systematic review. Surg. Endosc. 35, 4069\u20134084 (2021).","journal-title":"Surg. Endosc."},{"key":"1120_CR157","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1007\/s11695-023-06595-2","volume":"33","author":"A L\u00fcscher","year":"2023","unstructured":"L\u00fcscher, A. et al. Impact of preoperative psychiatric profile in bariatric surgery on long-term weight outcome. Obes. Surg. 33, 2072\u20132082 (2023).","journal-title":"Obes. Surg."},{"key":"1120_CR158","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer, X. et al. A randomized, controlled trial of 3.0\u2009mg of liraglutide in weight management. N. Engl. J. Med. 373, 11\u201322 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR159","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989\u20131002 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR160","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/HEP.0000000000000645","volume":"82","author":"LA Diaz","year":"2025","unstructured":"Diaz, L. A. et al. New insights into the molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease. Hepatology 82, 254\u2013271\u00a0(2025).","journal-title":"Hepatology"},{"key":"1120_CR161","doi-asserted-by":"publisher","first-page":"107312","DOI":"10.1016\/j.phrs.2024.107312","volume":"207","author":"N Bruns Vi","year":"2024","unstructured":"Bruns Vi, N., Tressler, E. H., Vendruscolo, L. F., Leggio, L. & Farokhnia, M. IUPHAR review\u00a0\u2014 glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target. Pharmacol. Res. 207, 107312 (2024).","journal-title":"Pharmacol. Res."},{"key":"1120_CR162","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1038\/s41591-023-02634-8","volume":"29","author":"L Leggio","year":"2023","unstructured":"Leggio, L. et al. GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Nat. Med. 29, 2993\u20132995 (2023).","journal-title":"Nat. Med."},{"key":"1120_CR163","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal, A. J. et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N. Engl. J. Med.\u00a0392, 2089\u20132099 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR164","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","volume":"184","author":"F Kanwal","year":"2024","unstructured":"Kanwal, F. et al. GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease. JAMA Intern. Med. 184, 1314\u20131323 (2024).","journal-title":"JAMA Intern. Med."},{"key":"1120_CR165","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205\u2013216 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR166","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal, A. J. et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N. Engl. J. Med. 391, 311\u2013319 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR167","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","volume":"82","author":"SA Harrison","year":"2025","unstructured":"Harrison, S. A. et al. Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study. J. Hepatol.\u00a082, 7\u201317 (2025).","journal-title":"J. Hepatol."},{"key":"1120_CR168","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","volume":"30","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal, A. J. et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat. Med. 30, 2037\u20132048 (2024).","journal-title":"Nat. Med."},{"key":"1120_CR169","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390, 497\u2013509 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR170","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1016\/S0168-8278(24)00708-6","volume":"80","author":"S Harrison","year":"2024","unstructured":"Harrison, S. et al. SAT-263 Resmetirom treatment of a subgroup of patients with possible MetALD enrolled in MAESTRO-NASH, a phase 3 NASH\/MASH serial liver biopsy study. J. Hepatol.\u00a080, S141\u2013S142 (2024).","journal-title":"J. Hepatol."},{"key":"1120_CR171","doi-asserted-by":"publisher","first-page":"110389","DOI":"10.1016\/j.isci.2024.110389","volume":"27","author":"T Wang","year":"2024","unstructured":"Wang, T. et al. The crosstalk between fibroblast growth factor 21 (FGF21) system and substance use. iScience 27, 110389 (2024).","journal-title":"iScience"},{"key":"1120_CR172","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1053\/j.gastro.2020.10.066","volume":"160","author":"KG Margolis","year":"2021","unstructured":"Margolis, K. G., Cryan, J. F. & Mayer, E. A. The microbiota\u2013gut\u2013brain axis: from motility to mood. Gastroenterology 160, 1486\u20131501 (2021).","journal-title":"Gastroenterology"},{"key":"1120_CR173","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1016\/j.cell.2023.05.001","volume":"186","author":"KM Schneider","year":"2023","unstructured":"Schneider, K. M. et al. The enteric nervous system relays psychological stress to intestinal inflammation. Cell\u00a0186, 2823\u20132838.e20 (2023).","journal-title":"Cell"},{"key":"1120_CR174","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/HEP.0000000000000344","volume":"80","author":"ML Smith","year":"2024","unstructured":"Smith, M. L., Wade, J. B., Wolstenholme, J. & Bajaj, J. S. Gut microbiome\u2013brain\u2013cirrhosis axis. Hepatology 80, 465\u2013485 (2024).","journal-title":"Hepatology"},{"key":"1120_CR175","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1097\/HEP.0000000000000474","volume":"78","author":"RM Carr","year":"2023","unstructured":"Carr, R. M. et al. An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations. Hepatology 78, 1843\u20131857 (2023).","journal-title":"Hepatology"},{"key":"1120_CR176","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","volume":"8","author":"SA Harrison","year":"2023","unstructured":"Harrison, S. A. et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol. Hepatol. 8, 1080\u20131093 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1120_CR177","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","volume":"392","author":"M Noureddin","year":"2025","unstructured":"Noureddin, M. et al. Efruxifermin in compensated liver cirrhosis caused by MASH. N. Engl. J. Med. 392, 2413\u20132424 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR178","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","volume":"389","author":"R Loomba","year":"2023","unstructured":"Loomba, R. et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N. Engl. J. Med. 389, 998\u20131008 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR179","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S2468-1253(25)00067-6","volume":"10","author":"R Loomba","year":"2025","unstructured":"Loomba, R. et al. Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Gastroenterol. Hepatol. 10, 734\u2013745 (2025).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1120_CR180","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41575-018-0099-1","volume":"16","author":"JS Bajaj","year":"2019","unstructured":"Bajaj, J. S. Alcohol, liver disease and the gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 16, 235\u2013246 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1120_CR181","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/hep.31496","volume":"73","author":"JS Bajaj","year":"2021","unstructured":"Bajaj, J. S. et al. A randomized clinical trial of fecal microbiota transplant for alcohol use disorder. Hepatology 73, 1688\u20131700 (2021).","journal-title":"Hepatology"},{"key":"1120_CR182","doi-asserted-by":"publisher","first-page":"100284","DOI":"10.1016\/j.jhepr.2021.100284","volume":"3","author":"C Bianco","year":"2021","unstructured":"Bianco, C., Casirati, E., Malvestiti, F. & Valenti, L. Genetic predisposition similarities between NASH and ASH: identification of new therapeutic targets. JHEP Rep. 3, 100284 (2021).","journal-title":"JHEP Rep."},{"key":"1120_CR183","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.jhep.2023.05.007","volume":"79","author":"D Lind\u00e9n","year":"2023","unstructured":"Lind\u00e9n, D. & Romeo, S. Therapeutic opportunities for the treatment of NASH with genetically validated targets. J. Hepatol. 79, 1056\u20131064 (2023).","journal-title":"J. Hepatol."},{"key":"1120_CR184","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1056\/NEJMc2402341","volume":"391","author":"E Fabbrini","year":"2024","unstructured":"Fabbrini, E. et al. Phase 1 trials of PNPLA3 siRNA in I148M homozygous patients with MAFLD. N. Engl. J. Med. 391, 475\u2013476 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR185","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jhep.2024.12.046","volume":"83","author":"J Armisen","year":"2025","unstructured":"Armisen, J. et al. AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials. J. Hepatol.\u00a083, 31\u201342 (2025).","journal-title":"J. Hepatol."},{"key":"1120_CR186","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.02.017","author":"LA Diaz","year":"2025","unstructured":"Diaz, L. A. et al. An expert consensus Delphi panel in MetALD: opportunities and challenges in clinical practice. Clin. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2025.02.017 (2025).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1120_CR187","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000386","volume":"8","author":"H Hagstr\u00f6m","year":"2024","unstructured":"Hagstr\u00f6m, H. et al. The future of international classification of diseases coding in steatotic liver disease: an expert panel Delphi consensus statement. Hepatol. Commun. 8, e0386 (2024).","journal-title":"Hepatol. Commun."},{"key":"1120_CR188","first-page":"00220","volume":"0","author":"JV Lazarus","year":"2024","unstructured":"Lazarus, J. V. et al. Best buy interventions to address the burden of steatotic liver disease. Lancet Gastroenterol. Hepatol. 0, 00220\u20136 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1120_CR189","unstructured":"World Health Organization. Global Status Report on Alcohol and Health 2018 (WHO, 2018)."},{"key":"1120_CR190","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","volume":"76","author":"JV Lazarus","year":"2022","unstructured":"Lazarus, J. V. et al. The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge? J. Hepatol.\u00a076, 771\u2013780 (2022).","journal-title":"J. Hepatol."},{"key":"1120_CR191","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S2468-1253(22)00008-5","volume":"7","author":"LA D\u00edaz","year":"2022","unstructured":"D\u00edaz, L. A. et al. The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas. Lancet Gastroenterol. Hepatol. 7, 552\u2013559 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1120_CR192","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jhep.2019.08.027","volume":"72","author":"JV Lazarus","year":"2020","unstructured":"Lazarus, J. V. et al. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. J. Hepatol. 72, 14\u201324 (2020).","journal-title":"J. Hepatol."},{"key":"1120_CR193","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jhep.2023.11.021","volume":"80","author":"L Retat","year":"2024","unstructured":"Retat, L. et al. Preventing liver disease with policy measures to tackle alcohol consumption and obesity: The HEPAHEALTH II study. J. Hepatol. 80, 543\u2013552 (2024).","journal-title":"J. Hepatol."},{"key":"1120_CR194","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jhep.2023.11.006","volume":"80","author":"LA D\u00edaz","year":"2024","unstructured":"D\u00edaz, L. A. et al. Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes. J. Hepatol.\u00a080, 409\u2013418 (2024).","journal-title":"J. Hepatol."},{"key":"1120_CR195","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/j.1530-0277.2012.01855.x","volume":"37","author":"SH Stewart","year":"2013","unstructured":"Stewart, S. H., Koch, D. G., Burgess, D. M., Willner, I. R. & Reuben, A. Sensitivity and specificity of urinary ethyl glucuronide and ethyl sulfate in liver disease patients. Alcohol. Clin. Exp. Res. 37, 150\u2013155 (2013).","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"1120_CR196","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/acer.12407","volume":"38","author":"PI Jatlow","year":"2014","unstructured":"Jatlow, P. I. et al. Ethyl glucuronide and ethyl sulfate assays in clinical trials, interpretation, and limitations: results of a dose ranging alcohol challenge study and 2 clinical trials. Alcohol. Clin. Exp. Res. 38, 2056\u20132065 (2014).","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"1120_CR197","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/acer.14512","volume":"45","author":"J Arnts","year":"2021","unstructured":"Arnts, J. et al. Diagnostic accuracy of biomarkers of alcohol use in patients with liver disease: a systematic review. Alcohol. Clin. Exp. Res. 45, 25\u201337 (2021).","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"1120_CR198","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/acer.12699","volume":"39","author":"JM Lowe","year":"2015","unstructured":"Lowe, J. M. et al. Determining ethyl glucuronide cutoffs when detecting self-reported alcohol use in addiction treatment patients. Alcohol. Clin. Exp. Res. 39, 905\u2013910 (2015).","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"1120_CR199","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1360-0443.2005.01245.x","volume":"101","author":"FM Wurst","year":"2006","unstructured":"Wurst, F. M. et al. Ethyl sulphate: a direct ethanol metabolite reflecting recent alcohol consumption. Addiction 101, 204\u2013211 (2006).","journal-title":"Addiction"},{"key":"1120_CR200","doi-asserted-by":"crossref","unstructured":"Poynard, T. & Imbert-Bismut, F. in Zakim and Boyer\u2019s Hepatology: A Textbook of Liver Disease (eds Boyer, T. D., Manns, M. P. & Sanyal, A. J.) 201\u2013215 (Elsevier, 2011).","DOI":"10.1016\/B978-1-4377-0881-3.00014-0"},{"key":"1120_CR201","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/j.1530-0277.1996.tb05261.x","volume":"20","author":"RF Anton","year":"1996","unstructured":"Anton, R. F., Moak, D. H. & Latham, P. Carbohydrate-deficient transferrin as an indicator of drinking status during a treatment outcome study. Alcohol. Clin. Exp. Res. 20, 841\u2013846 (1996).","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"1120_CR202","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1053\/j.gastro.2006.08.020","volume":"131","author":"W Dunn","year":"2006","unstructured":"Dunn, W. et al. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology 131, 1057\u20131063 (2006).","journal-title":"Gastroenterology"},{"key":"1120_CR203","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1148\/radiol.2016160131","volume":"283","author":"Y Zhuang","year":"2017","unstructured":"Zhuang, Y. et al. Two-dimensional shear-wave elastography performance in the noninvasive evaluation of liver fibrosis in patients with chronic hepatitis B: comparison with serum fibrosis indexes. Radiology 283, 873\u2013882 (2017).","journal-title":"Radiology"},{"key":"1120_CR204","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/gutjnl-2020-323419","volume":"71","author":"J Trebicka","year":"2022","unstructured":"Trebicka, J. et al. Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. Gut 71, 402\u2013414 (2022).","journal-title":"Gut"},{"key":"1120_CR205","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1148\/radiol.2020191481","volume":"295","author":"M Wu","year":"2020","unstructured":"Wu, M. et al. Liver stiffness measured with two-dimensional shear-wave elastography is predictive of liver-related events in patients with chronic liver disease due to hepatis B viral infection. Radiology 295, 353\u2013360 (2020).","journal-title":"Radiology"},{"key":"1120_CR206","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cgh.2022.06.013","volume":"21","author":"G Pennisi","year":"2023","unstructured":"Pennisi, G. et al. AGILE 3+ score for the diagnosis of advanced fibrosis and for predicting liver-related events in NAFLD. Clin. Gastroenterol. Hepatol. 21, 1293\u20131302.e5 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1120_CR207","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000055","volume":"7","author":"M Noureddin","year":"2023","unstructured":"Noureddin, M. et al. Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores. Hepatol. Commun. 7, e0055 (2023).","journal-title":"Hepatol. Commun."},{"key":"1120_CR208","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jhep.2022.10.034","volume":"78","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal, A. J. et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using fibroScan-based Agile scores. J. Hepatol. 78, 247\u2013259 (2023).","journal-title":"J. Hepatol."},{"key":"1120_CR209","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0303971","volume":"19","author":"M-G Taru","year":"2024","unstructured":"Taru, M.-G. et al. FAST and Agile \u2014 the MASLD drift: validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven NAFLD patients meeting MASLD criteria of prevalent Caucasian origin. PLoS ONE 19, e0303971 (2024).","journal-title":"PLoS ONE"},{"key":"1120_CR210","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/liv.15415","volume":"43","author":"M Braude","year":"2023","unstructured":"Braude, M. et al. Liver stiffness (Fibroscan\u00ae) is a predictor of all-cause mortality in people with non-alcoholic fatty liver disease. Liver Int. 43, 90\u201399 (2023).","journal-title":"Liver Int."},{"key":"1120_CR211","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/liv.15919","volume":"44","author":"H Hegmar","year":"2024","unstructured":"Hegmar, H. et al. Liver stiffness predicts progression to liver-related events in patients with chronic liver disease \u2014 a cohort study of 14 414 patients. Liver Int. 44, 1689\u20131699 (2024).","journal-title":"Liver Int."},{"key":"1120_CR212","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1053\/j.gastro.2017.03.017","volume":"152","author":"JK Lim","year":"2017","unstructured":"Lim, J. K., Flamm, S. L., Singh, S. & Falck-Ytter, Y. T.Clinical Gguidelines Committee of the American Gastroenterological Association American Gastroenterological Association Institute guideline on the role of elastography in the evaluation of liver fibrosis. Gastroenterology 152, 1536\u20131543 (2017).","journal-title":"Gastroenterology"},{"key":"1120_CR213","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1111\/liv.15595","volume":"43","author":"S Johansen","year":"2023","unstructured":"Johansen, S. et al. Validation of scores of PRO-C3 to predict liver-related events in alcohol-related liver disease. Liver Int. 43, 1486\u20131496 (2023).","journal-title":"Liver Int."},{"key":"1120_CR214","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/hep.30163","volume":"69","author":"SJ Daniels","year":"2019","unstructured":"Daniels, S. J. et al. ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology 69, 1075\u20131086 (2019).","journal-title":"Hepatology"},{"key":"1120_CR215","doi-asserted-by":"publisher","first-page":"G1009","DOI":"10.1152\/ajpgi.00283.2016","volume":"311","author":"MA Karsdal","year":"2016","unstructured":"Karsdal, M. A. et al. Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. Am. J. Physiol. Gastrointest. Liver Physiol. 311, G1009\u2013G1017 (2016).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"1120_CR216","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30457-y","volume":"8","author":"Y Luo","year":"2018","unstructured":"Luo, Y. et al. An evaluation of the collagen fragments related to fibrogenesis and fibrolysis in nonalcoholic steatohepatitis. Sci. Rep. 8, 12414 (2018).","journal-title":"Sci. Rep."},{"key":"1120_CR217","doi-asserted-by":"publisher","first-page":"e1356","DOI":"10.1210\/clinem\/dgab897","volume":"107","author":"P Bel Lassen","year":"2022","unstructured":"Bel Lassen, P. et al. Fibrogenesis marker PRO-C3 is higher in advanced liver fibrosis and improves in patients undergoing bariatric surgery. J. Clin. Endocrinol. Metab. 107, e1356\u2013e1366 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1120_CR218","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1111\/liv.15878","volume":"44","author":"L-J Tang","year":"2024","unstructured":"Tang, L.-J. et al. Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort. Liver Int. 44, 1129\u20131141 (2024).","journal-title":"Liver Int."},{"key":"1120_CR219","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1111\/jgh.16240","volume":"38","author":"M Liu","year":"2023","unstructured":"Liu, M. et al. Evaluation of blood-based PRO-C3 testing as a diagnostic marker for staging liver fibrosis: a systematic review and meta-analysis. J. Gastroenterol. Hepatol. 38, 1018\u20131027 (2023).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1120_CR220","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1136\/gut.2009.203166","volume":"59","author":"J Parkes","year":"2010","unstructured":"Parkes, J. et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 59, 1245\u20131251 (2010).","journal-title":"Gut"},{"key":"1120_CR221","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/liv.12896","volume":"36","author":"KM Irvine","year":"2016","unstructured":"Irvine, K. M. et al. The enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. Liver Int. 36, 370\u2013377 (2016).","journal-title":"Liver Int."},{"key":"1120_CR222","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/hepr.13495","volume":"50","author":"C Inadomi","year":"2020","unstructured":"Inadomi, C. et al. Accuracy of the enhanced liver fibrosis test, and combination of the enhanced liver fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease. Hepatol. Res. 50, 682\u2013692 (2020).","journal-title":"Hepatol. Res."},{"key":"1120_CR223","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1111\/liv.12760","volume":"35","author":"KJ Fagan","year":"2015","unstructured":"Fagan, K. J. et al. ELF score li\u22659.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity. Liver Int. 35, 1673\u20131681 (2015).","journal-title":"Liver Int."},{"key":"1120_CR224","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/liv.14669","volume":"41","author":"J Lee","year":"2021","unstructured":"Lee, J. et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review. Liver Int. 41, 261\u2013270 (2021).","journal-title":"Liver Int."},{"key":"1120_CR225","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","volume":"8","author":"FE M\u00f3zes","year":"2023","unstructured":"M\u00f3zes, F. E. et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol. Hepatol. 8, 704\u2013713 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1120_CR226","doi-asserted-by":"publisher","first-page":"100780","DOI":"10.1016\/j.lanepe.2023.100780","volume":"36","author":"QM Anstee","year":"2024","unstructured":"Anstee, Q. M. et al. Prognostic utility of fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: a longitudinal cohort study. Lancet Reg. Health Eur. 36, 100780 (2024).","journal-title":"Lancet Reg. Health Eur."},{"key":"1120_CR227","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1097\/HEP.0000000000001045","volume":"81","author":"Y Shang","year":"2025","unstructured":"Shang, Y. et al. Association between longitudinal biomarkers and major adverse liver outcomes in patients with non-cirrhotic metabolic dysfunction-associated steatotic liver disease. Hepatology 81, 1501\u20131511 (2025).","journal-title":"Hepatology"},{"key":"1120_CR228","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","volume":"71","author":"FE M\u00f3zes","year":"2022","unstructured":"M\u00f3zes, F. E. et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut 71, 1006\u20131019 (2022).","journal-title":"Gut"},{"key":"1120_CR229","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1002\/hep.31599","volume":"73","author":"EM Brunt","year":"2021","unstructured":"Brunt, E. M. et al. NAFLD: Reporting histologic findings in clinical practice. Hepatology 73, 2028\u20132038 (2021).","journal-title":"Hepatology"},{"key":"1120_CR230","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.clinthera.2021.01.012","volume":"43","author":"S Kogachi","year":"2021","unstructured":"Kogachi, S. & Noureddin, M. Noninvasive evaluation for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin. Ther. 43, 455\u2013472 (2021).","journal-title":"Clin. Ther."},{"key":"1120_CR231","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1007\/s00330-024-11001-1","volume":"35","author":"N Azizi","year":"2025","unstructured":"Azizi, N. et al. Evaluation of MRI proton density fat fraction in hepatic steatosis: a systematic review and meta-analysis. Eur. Radiol. 35, 1794\u20131807 (2025).","journal-title":"Eur. Radiol."},{"key":"1120_CR232","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.cgh.2021.09.041","volume":"20","author":"A Andersson","year":"2022","unstructured":"Andersson, A. et al. Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis. Clin. Gastroenterol. Hepatol. 20, 2451\u20132461.e3 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1120_CR233","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238717","volume":"15","author":"J Lee","year":"2020","unstructured":"Lee, J. et al. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: a systematic review and meta-analysis. PLoS ONE 15, e0238717 (2020).","journal-title":"PLoS ONE"},{"key":"1120_CR234","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jhep.2024.08.031","volume":"82","author":"N Alkhouri","year":"2025","unstructured":"Alkhouri, N. et al. Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH. J. Hepatol. 82, 438\u2013445 (2025).","journal-title":"J. Hepatol."},{"key":"1120_CR235","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.addbeh.2015.06.042","volume":"50","author":"JS Simons","year":"2015","unstructured":"Simons, J. S., Wills, T. A., Emery, N. N. & Marks, R. M. Quantifying alcohol consumption: Self-report, transdermal assessment, and prediction of dependence symptoms. Addict. Behav. 50, 205\u2013212 (2015).","journal-title":"Addict. Behav."},{"key":"1120_CR236","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/jat\/bkab086","volume":"46","author":"L Skaggs","year":"2022","unstructured":"Skaggs, L., Heizler, A., Kalscheur, D., Miles, A. & Barkholtz, H. M. Comparison of breath- and blood-alcohol concentrations in a controlled drinking study. J. Anal. Toxicol. 46, 683\u2013688 (2022).","journal-title":"J. Anal. Toxicol."},{"key":"1120_CR237","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/alcalc\/ags065","volume":"47","author":"A Helander","year":"2012","unstructured":"Helander, A., P\u00e9ter, O. & Zheng, Y. Monitoring of the alcohol biomarkers PEth, CDT and EtG\/EtS in an outpatient treatment setting. Alcohol Alcohol. 47, 552\u2013557 (2012).","journal-title":"Alcohol Alcohol."},{"key":"1120_CR238","doi-asserted-by":"publisher","first-page":"12175","DOI":"10.3390\/ijms241512175","volume":"24","author":"M Perilli","year":"2023","unstructured":"Perilli, M. et al. Phosphatidylethanol (PEth) in blood as a marker of unhealthy alcohol use: a systematic review with novel molecular insights. Int. J. Mol. Sci. 24, 12175 (2023).","journal-title":"Int. J. Mol. Sci."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-025-01120-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-025-01120-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-025-01120-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:01:52Z","timestamp":1766059312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-025-01120-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":238,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1120"],"URL":"https:\/\/doi.org\/10.1038\/s41575-025-01120-5","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"28 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the \u201cELF test\u201d row of Table 2, the second column originally read \u201cIncludes PRO-C3, hyaluronic acid and TIMP1\u201d and has now been corrected to \u201cIncludes amino-terminal propeptide of type III procollagen, hyaluronic acid and TIMP1\u201d in the HTML and PDF versions of the article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M. Thiele received speaker\u2019s fee from Echosens, Madrigal\u00a0Pharmaceuticals, Takeda and Novo Nordisk; received advisory fees from Boehringer Ingelheim, AstraZeneca, Novo Nordisk and GSK; and is co-founder of Evido. D.Q.H. has served as an advisory board member for Gilead\u00a0Sciences and Roche. B.P.L. served as a consultant or advisory board member for AltImmune, DURECT, Gilead\u00a0Sciences,\u00a0GSK, HepaTx, Ipsen and Novo Nordisk; and received a research grant from Siemens Healthineers. R.B. consults for Boehringer Ingelheim,\u00a0GSK and\u00a0Novo Nordisk. J.M. serves as advisory board member for 89bio, Eli Lilly,\u00a0GSK and Novo Nordisk. M.C.M. serves as an advisory board member for GSK. M.E.R. is scientific adviser or consultant for Akero Therapeutics, Boehringer Ingelheim, Cytodyn, Echosens, GSK, Intercept Pharmaceuticals, Madrigal\u00a0Pharmaceuticals, NGM Biopharmaceuticals, Novo Nordisk and Sonic Incytes. V.W.-S.W. served as a consultant or advisory board member for AbbVie, AstraZeneca, Boehringer Ingelheim, Echosens, Eli Lilly, Gilead Sciences, Intercept\u00a0Pharmaceuticals, Inventiva, Merck, Novo Nordisk, Pfizer, Sagimet Biosciences, TARGET PharmaSolutions and Visirna; served as a speaker for Abbott, AbbVie, Echosens, Gilead Sciences, Novo Nordisk and Unilab; has received a research grant from Gilead Sciences; and is a co-founder of Illuminatio Medical Technology. A.K. has served as a speaker for Norgine,\u00a0Novo Nordisk and Siemens; participated in advisory boards for Boehringer Ingelheim,\u00a0GSK, Novo Nordisk and\u00a0Siemens, all outside the submitted work; has received research support from AstraZeneca, Echosense,\u00a0Nordic Bioscience and\u00a0Siemens; and is a board member and co-founder of Evido. M.A. consults for AstraZeneca\u00a0and\u00a0Inventiva; and has served as a speaker for Siemens. R.L. serves as a consultant to 89bio, Aardvark Therapeutics, Altimmune, Amgen, Anylam\/Regeneron, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, CohBar, Eli Lilly, Galmed, Gilead\u00a0Sciences, Glympse Bio, Hightide, Inipharma, Intercept\u00a0Pharmaceuticals, Inventiva, Ionis, Janssen, Madrigal\u00a0Pharmaceuticals, Merck, Metacrine, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Sagimet\u00a0Bioscience, Terns Pharmaceuticals,\u00a0Theratechnologies and Viking Therapeutics; his institutions received research grants from Arrowhead Pharmaceuticals, AstraZeneca, Boehringer\u00a0Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead\u00a0Sciences, Hanmi, Intercept\u00a0Pharmaceuticals, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Pfizer, Sonic Incytes and Terns Pharmaceuticals; and he is a co-founder of LipoNexus. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}